coronaviru
diseas
becom
pandem
caus
million
infect
tenthousand
death
short
period
time
worldwid
howev
littl
known
patholog
mechan
report
clinic
studi
specif
treatment
object
purpos
studi
determin
clinic
efficaci
intraven
immunoglobulin
ivig
therapi
patient
coronaviru
covid
system
infecti
diseas
mainli
caus
sever
acut
respiratori
syndrom
coronaviru
critic
lifethreaten
multiorgan
dysfunct
syndrom
dysregul
result
host
respons
character
refractori
hypoxemia
caus
acut
respiratori
distress
syndrom
ard
decemb
april
peopl
china
infect
peopl
die
global
million
peopl
infect
near
peopl
die
includ
larg
number
health
worker
becom
seriou
problem
face
medic
staff
research
accord
report
gener
mortal
case
incid
critic
includ
sever
critic
type
defin
infect
publish
nation
health
commiss
china
trial
version
mortal
current
believ
primarili
infect
lung
subsequ
caus
system
inflamm
immun
respons
disord
ultim
lead
multipl
organ
injuri
even
death
howev
effect
therapeut
method
lack
avail
clinic
treatment
strategi
critic
mainli
antivir
oxygen
therapi
well
organ
symptomat
support
includ
mechan
ventil
even
extracorpor
membran
oxygen
ecmo
cardiopulmonari
support
continu
renal
replac
therapi
crrt
howev
clinic
efficaci
strategi
still
uncertain
clinic
test
autopsi
result
suggest
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
inflamm
immun
respons
caus
viru
infect
key
factor
progress
diseas
poor
prognosi
underli
mechan
remain
unclear
target
intraven
immunoglobulin
ivig
one
main
treatment
measur
howev
due
lack
clinic
trial
efficaci
ivig
yet
determin
clinic
applic
still
controversi
human
immunoglobulin
intraven
inject
liquid
prepar
contain
human
immunoglobulin
made
normal
human
plasma
contain
igg
antibodi
broadspectrum
antivir
bacteri
pathogen
ivig
rapidli
increas
igg
level
blood
directli
neutral
exogen
antigen
regul
multipl
immun
function
includ
regul
immun
media
improv
immun
capac
natur
immun
cell
lymphocyt
ivig
wildli
use
treatment
sever
bacteri
viral
infect
sepsi
studi
demonstr
clinic
efficaci
especi
case
viral
infecti
diseas
wherea
studi
fail
show
therapeut
efficaci
lead
great
controversi
clinic
applic
acut
respiratori
viru
infect
latest
version
china
therapeut
guidelin
suggest
ivig
select
treatment
method
howev
due
lack
specif
antibodi
efficaci
ivig
remain
elucid
notic
use
ivig
recommend
list
select
method
therapeut
guidelin
order
confirm
potenti
therapeut
efficaci
ivig
retrospect
collect
clinic
outcom
data
critic
patient
includ
sever
type
critic
type
govern
design
treatment
center
three
citi
wuhan
guangzhou
shenzhen
china
use
ivig
exposur
factor
analyz
symptom
outcom
date
first
clinic
multicent
cohort
studi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ivig
treatment
larg
number
critic
ill
patient
studi
provid
import
inform
clinic
applic
ivig
treatment
infect
includ
patient
select
administr
time
dosag
multicent
retrospect
cohort
studi
perform
eight
govern
design
treatment
center
patient
icu
gener
ward
citi
china
includ
wuhan
guangzhou
shenzhen
data
collect
period
decemb
march
data
cutoff
date
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
design
data
collect
form
includ
demograph
clinic
treatment
laboratori
data
prognosi
extract
electron
medic
record
detail
clinic
data
prescript
ivig
data
correspond
time
period
nonivig
group
collect
respect
whether
use
ivig
dosag
cours
decid
doctor
charg
comparison
conduct
accord
whether
ivig
use
primari
endpoint
hospit
mortal
total
inhospit
day
total
durat
diseas
secondari
endpoint
meanwhil
paramet
inflamm
organ
function
measur
influenc
factor
determin
cox
regress
analysi
outcom
surviv
curv
carri
accord
clinic
classif
ivig
dosag
time
studi
approv
research
ethic
commiss
gener
hospit
southern
theater
command
pla
requir
inform
consent
waiv
ethic
commiss
critic
articl
defin
combin
term
sever
type
critic
type
classifi
follow
chines
recommend
diagnosi
treatment
novel
coronaviru
infect
trial
version
publish
nation
health
commiss
china
ivig
repres
human
immunoglobulin
intraven
inject
liquid
prepar
contain
human
immunoglobulin
made
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
normal
human
plasma
contain
igg
antibodi
broadspectrum
antivir
bacteri
pathogen
ivig
rapidli
increas
level
igg
blood
recipi
intraven
infus
enhanc
antiinfect
abil
immun
regul
function
bodi
categor
data
summar
number
percentag
intergroup
comparison
perform
use
mannwhitney
u
test
fisher
exact
test
continu
variabl
express
arithmet
mean
standard
deviat
sd
median
interquartil
rang
depend
whether
show
gaussian
distribut
continu
data
gaussian
distribut
compar
student
test
oneway
anova
nongaussian
distribut
wilcoxon
ranksum
test
compar
white
blood
cell
lymphocyt
neutrophil
monocyt
count
igiv
nonigiv
group
determin
independ
effect
mortal
critic
patient
account
signific
confound
cox
proport
hazard
model
use
fulli
adjust
model
odd
ratio
confid
interv
level
ci
moreov
analysi
mortal
kaplanmei
surviv
curv
logrank
test
use
statist
analysi
perform
use
spss
window
version
statist
packag
spss
inc
chicago
il
p
valu
twotail
consid
statist
signific
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
clinic
data
patient
collect
confirm
critic
exclud
patient
due
miss
key
inform
patient
includ
final
analysi
figur
detail
demograph
clinic
profil
data
critic
ill
patient
baselin
summar
tabl
patient
mean
age
ys
iqr
mean
bodi
temperatur
iqr
nearli
half
patient
comorbid
mainli
hypertens
diabet
coronari
heart
diseas
sever
type
critic
type
case
use
ivig
case
comparison
baselin
characterist
two
group
show
diseas
sever
ivig
group
present
older
age
higher
apachii
score
sofa
score
higher
level
total
bilirubin
direct
bilirubin
creatinin
creactiv
protein
lactat
lower
platelet
lymphocyt
count
p
decreas
pao
fio
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
analysi
primari
secondari
outcom
patient
show
die
day
die
day
death
includ
sever
type
patient
critic
type
patient
ivig
group
die
within
total
die
nonivig
group
die
within
total
die
signific
differ
mortal
ivig
group
non
compar
two
group
hospit
day
total
durat
diseas
longer
ivig
group
p
tabl
number
lymphocyt
still
lower
p
crp
still
higher
p
supplementari
tabl
consist
seriou
initi
condit
ivig
group
order
correct
bia
differ
two
group
basic
condit
prognosi
multivari
cox
regress
analysi
perform
gender
age
comorbid
apach
ii
score
sofa
score
temperatur
white
blood
cell
count
neutrophil
count
lymphocyt
count
fibrinogen
creatinin
pao
fio
lactic
acid
clinic
classif
ivig
use
found
lower
lymphocyt
count
associ
sever
classif
higher
mortal
applic
ivig
significantli
decreas
mortal
hr
ci
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
accord
result
multivari
analysi
deep
analysi
carri
differ
subgroup
result
show
ivig
could
significantli
decreas
mortal
patient
critic
type
effect
mortal
inhospit
stay
p
tabl
addit
ivig
also
significantli
decreas
procalcitonin
pct
lactic
acid
level
critic
type
patient
p
supplementari
tabl
suggest
ivig
decreas
inflammatori
respons
may
improv
microcircul
perfus
howev
sever
type
patient
differ
mortal
ivig
group
non
ivig
group
p
length
inhospit
stay
ivig
group
chang
tabl
moreov
differ
surviv
rate
two
group
supplementari
figur
analys
perform
apachii
score
pao
fio
lymphocyt
count
l
l
sofa
score
result
show
differ
mortal
ivig
non
ivig
group
supplementari
tabl
comparison
paramet
inflamm
respons
organ
function
ivig
significantli
decreas
pct
level
improv
pao
fio
p
supplementari
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
compar
low
dose
group
gd
comparison
subgroup
differ
type
show
high
dose
ivig
gd
could
significantli
reduc
mortal
critic
type
patient
p
p
perspect
tabl
increas
surviv
time
p
supplementari
tabl
confirm
effect
ivig
applic
time
outcom
patient
subgroup
time
admiss
begin
ivig
treatment
admiss
compar
result
show
earli
administr
ivig
could
significantli
reduc
mortal
p
tabl
total
inhospit
stay
total
cours
diseas
respect
significantli
increas
surviv
time
supplementari
figur
analysi
show
earli
use
ivig
could
also
significantli
increas
pao
fio
p
decreas
level
pct
crp
supplementari
tabl
suggest
earli
use
ivig
potenti
abl
improv
inflammatori
respons
organ
function
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
pandem
outbreak
rapidli
spread
world
result
one
hundr
thousand
global
death
due
lack
wellestablish
treatment
knowledg
multicent
retrospect
cohort
studi
first
clinic
evalu
larg
number
case
effici
ivig
treatment
critic
patient
basic
condit
patient
ivig
group
seriou
result
show
critic
patient
ivig
effect
mortal
notabl
multivari
regress
show
classif
ivig
use
factor
relat
hazard
ratio
death
subgroup
analysi
show
critic
type
patient
ivig
could
significantli
decreas
inflammatori
respons
improv
organ
function
reduc
mortal
rate
prolong
surviv
time
furthermor
studi
show
earli
use
ivig
day
high
dose
gd
exhibit
significantli
cur
effect
noteworthi
result
indic
earli
high
dose
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
inflammatori
effect
increas
certain
cytokin
secret
promot
cell
b
cell
prolifer
differenti
therefor
immunoglobulin
thought
benefici
treatment
previou
studi
treatment
sar
mer
suggest
benefici
role
high
dose
immunoglobulin
administr
sinc
immunoglobulin
specif
antibodi
viru
clinic
evid
efficaci
limit
research
held
oppos
view
usag
immunoglobulin
acut
viru
infect
treatment
guidanc
china
recommend
immunoglobulin
usag
differ
data
current
studi
show
ivig
improv
outcom
overal
enrol
critic
patient
howev
multivari
regress
subgroup
analysi
show
ivig
could
improv
prognosi
critic
type
patient
one
explan
sever
type
case
lower
organ
injuri
mortal
similar
previou
studi
recommend
dose
immunoglobulin
day
howev
present
studi
dose
use
differ
among
differ
center
physician
rang
treatment
period
rang
day
subgroup
analysi
found
high
dose
gd
equival
show
cur
effect
consist
usag
immunoglobulin
treat
sepsi
effect
high
dose
high
dose
immunoglobulin
would
abl
rapidli
increas
concentr
circul
play
role
enhanc
immun
antivir
function
current
studi
suggest
import
earli
use
immunoglobulin
patient
immunoglobulin
affect
innat
adapt
immun
system
directli
bind
pathogen
antigen
usual
appear
circul
earli
stage
follow
viru
infect
base
current
understand
pathogenesi
late
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
stage
excess
inflammatori
respons
develop
organ
dysfunct
occur
efficaci
administr
immunoglobulin
would
larg
limit
data
show
immunoglobulin
employ
within
day
hospit
admiss
could
improv
prognosi
found
patient
enrol
ivig
group
sever
condit
evidenc
higher
apach
ii
sofa
score
higher
level
lactat
well
decreas
lymphocyt
count
oxygen
index
multicent
retrospect
studi
compar
sar
mer
demonstr
sever
exception
includ
prolong
cours
potenti
asymptomat
hypoxia
sever
lung
injuri
unexpect
progress
induc
death
clinic
featur
urgent
call
exploratori
treatment
attempt
ivig
one
attempt
exclud
influenc
bia
studi
perform
regress
analysi
potenti
factor
univari
surviv
analysi
show
apach
ii
sofa
sore
risk
factor
relat
outcom
analysi
found
apach
ii
sofa
score
rel
low
enrol
patient
consist
characterist
diseas
ie
patient
sever
lung
injuri
organ
injuri
cox
regress
confirm
critic
type
patient
show
poor
prognosi
ivig
improv
surviv
rate
although
ivig
show
therapeut
effect
whole
cohort
benefici
critic
type
patient
addit
cox
regress
also
show
lymphopenia
risk
poor
prognosi
observ
consist
previou
studi
report
patient
show
lymphocyt
count
decreas
persist
lymphopenia
relat
poor
outcom
howev
subgroup
analysi
base
lymphocyt
count
show
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
improv
outcom
relat
ivig
intervent
explan
uncertain
yet
futur
studi
role
ivig
regul
lymphocyt
number
function
need
limit
present
studi
firstli
case
eight
clinic
center
may
still
lack
suffici
repres
secondli
dose
time
ivig
administr
center
may
exactli
consist
thirdli
limit
clinic
workload
situat
evalu
immunoglobulin
effect
mainli
base
clinic
manifest
rather
direct
cellular
molecular
assess
includ
viral
load
lymphocyt
activ
progress
recognit
larg
case
random
control
studi
develop
evalu
system
need
confirm
effici
ivig
treatment
conclus
present
studi
first
clinic
research
evalu
effici
ivig
treatment
critic
patient
data
demonstr
earli
applic
high
dose
ivig
improv
prognosi
patient
critic
type
studi
provid
import
inform
clinic
applic
ivig
treatment
infect
includ
patient
select
administr
time
dosag
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
author
review
manuscript
approv
public
avail
data
materi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
data
set
use
andor
analyz
current
studi
avail
correspond
author
reason
request
author
declar
compet
interest
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
tabl
primari
secondari
outcom
ivig
non
ivig
group
tabl
risk
factor
associ
mortal
hospit
tabl
effect
ivig
treatment
primari
secondari
outcom
analysi
subgroup
critic
sever
type
tabl
effect
differ
dose
ivig
treatment
primari
secondari
outcom
patient
tabl
effect
differ
dose
ivig
primari
secondari
outcom
critic
sever
subgroup
tabl
effect
time
ivig
use
primari
secondari
outcom
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
effect
dose
ivig
treatment
mortal
patient
sever
type
figur
effect
time
ivig
treatment
mortal
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
inhospit
day
inhospit
day
tabl
effect
time
ivig
use
primari
secondari
outcom
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
